[Modifications of the lipid metabolism induced by interferon beta in multiple sclerosis patients and its relationship with the disease activity].
BACKGROUND
It has been recently suggested that total cholesterol and low density lipoproteins (LDL) levels can behave as biological markers of activity in demyelinating diseases. Thus, our aim has been to describe the modifications of the plasma levels of total cholesterol and triglyceride due to treatment with interferon-beta in multiple sclerosis (MS) patients and to determine their relationship with the disease activity.


METHODS
Study of the follow-up of MS patients under treatment with interferon-beta. Clinical and analytical controls were performed before initiating treatment and than at 1, 3, 6, 12, 18 and 24 months of its initiation.


RESULTS
Fifty six patients have been studied, 41 of them women. Mean age was 37.4 years. Fifty were relapsing- remitting forms and the rest secondary progressive forms. The mean plasma levels of triglyceride increased and total cholesterol levels diminished during the 24 months of treatment with interferon, mainly in the first 3 months. No statistically significant relationship was found between disease activity and mean plasma levels of triglyceride and total cholesterol before the beginning of the treatment and during the period of follow-up.


CONCLUSIONS
Treatment with interferon-beta in the MS patients originates changes in the plasma lipid profile, but neither these changes nor the plasma lipid levels before the treatment behave as biological markers of disease activity.
Ara
J R
JR
Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza. jrara@able.es
López
A
A
Martín
J
J
Alarcia
R
R
Oliván
J A
JA
de Val
V
V
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood*; D005260:Female; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000188:drug therapy* / Q000378:metabolism; D012189:Retrospective Studies; D014280:Triglycerides / Q000097:blood*
D000276:Adjuvants, Immunologic; D015415:Biomarkers; D014280:Triglycerides; D016899:Interferon-beta; D002784:Cholesterol